Nitric oxide and peroxynitrite in health and disease

P Pacher, JS Beckman, L Liaudet - Physiological reviews, 2007 - journals.physiology.org
The discovery that mammalian cells have the ability to synthesize the free radical nitric oxide
(NO) has stimulated an extraordinary impetus for scientific research in all the fields of …

Role of poly (ADP‐ribose) polymerase 1 (PARP‐1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors

P Pacher, C Szabó - Cardiovascular drug reviews, 2007 - Wiley Online Library
Accumulating evidence suggests that the reactive oxygen and nitrogen species are
generated in cardiomyocytes and endothelial cells during myocardial ischemia/reperfusion …

NO and CO differentially activate soluble guanylyl cyclase via a heme pivot‐bend mechanism

X Ma, N Sayed, A Beuve, F Van Den Akker - The EMBO journal, 2007 - embopress.org
Diatomic ligand discrimination by soluble guanylyl cyclase (sGC) is paramount to
cardiovascular homeostasis and neuronal signaling. Nitric oxide (NO) stimulates sGC …

Natriuretic peptides and therapeutic applications

CYW Lee, JC Burnett - Heart failure reviews, 2007 - Springer
Since the discovery of atrial natriuretic factor by de Bold et al., there has been tremendous
progress in our understanding of the physiologic, diagnostic and therapeutic roles of the …

Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface

TA McKinsey, DA Kass - Nature Reviews Drug Discovery, 2007 - nature.com
Pathological stress from cardiovascular disease stimulates hypertrophy of heart cells, which
increases the risk of cardiac morbidity and mortality. Recent evidence has indicated that …

Redox features of the cell: a gender perspective

W Malorni, I Campesi, E Straface, S Vella… - Antioxidants & redox …, 2007 - liebertpub.com
Reactive oxygen and nitrogen species have been implicated in diverse subcellular activities,
including cell proliferation, differentiation and, in some instances, cell injury and death. The …

Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure

G Boerrigter, LC Costello-Boerrigter, A Cataliotti… - …, 2007 - Am Heart Assoc
Soluble guanylate cyclase is a heterodimeric enzyme with a prosthetic heme group that, on
binding of its main ligand, NO, generates the second messenger cGMP. Unlike conventional …

Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation

OV Evgenov, DS Kohane, KD Bloch… - American journal of …, 2007 - atsjournals.org
Rationale: Nitric oxide–independent agonists of soluble guanylate cyclase (sGC) have been
developed. Objectives: We tested whether inhalation of novel dry-powder microparticle …

Nitric oxide–independent stimulation of soluble guanylate cyclase with BAY 41‐2272 in cardiovascular disease

G Boerrigter, JC Burnett Jr - Cardiovascular drug reviews, 2007 - Wiley Online Library
The nitric oxide (NO)–soluble guanylate cyclase (sGC)‐cyclic 3′, 5′‐guanosine
monophosphate (cGMP) pathway plays an important role in cardiovascular regulation by …

Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy

A Cogolludo, L Moreno, E Villamor - Pharmacology, 2007 - karger.com
Pulmonary vasoconstriction is believed to be an early component of pulmonary arterial
hypertension. Intracellular calcium concentration ([Ca2+] i) is a major trigger for pulmonary …